Investing

Fund Managers Pile Into Big Dividend Health Care Stocks: 8 'Strong Buy' Winners

Amgen

This biotech giant remains a safer way to play the massive potential growth in biosimilars. Amgen Inc. (NASDAQ: AMGN) discovers, develops, manufactures and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.

The company’s products include the following:

  • Enbrel to treat plaque psoriasis, rheumatoid arthritis and psoriatic arthritis
  • Neulasta reduces the chance of infection due a low white blood cell count in patients with cancer
  • Prolia to treat postmenopausal women with osteoporosis
  • Xgeva for skeletal-related events prevention
  • Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behcet’s disease
  • Aranesp to treat a lower-than-normal number of red blood cells and anemia
  • Kyprolis to treat patients with relapsed or refractory multiple myeloma
  • Repatha, which reduces the risks of myocardial infarction, stroke and coronary revascularization

Shareholders receive a 3.29% dividend. The Jefferies target price is $280, while the consensus target for Amgen stock is $248.49. The final trade for Thursday came in at $235.86.

Bristol-Myers Squibb

This top company remains a solid pharmaceutical stock to own long-term. Bristol Myers Squibb Co. (NYSE: BMY) discovers, develops, licenses, manufactures and markets pharmaceutical products worldwide in the hematology, oncology, cardiovascular and immunology therapeutic classes.

Its products include the following:

  • Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma
  • Opdivo for anti-cancer indications
  • Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders
  • Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
  • Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia
  • Yervoy for the treatment of patients with unresectable or metastatic melanoma
  • Abraxane, a protein-bound chemotherapy product
  • Reblozyl for the treatment of anemia in adult patients with beta thalassemia

Shareholders receive a 3.06% dividend. The $78 BofA Securities price target compares with a $74.13 consensus target. Bristol-Myers Squibb stock closed on Thursday at $70.52.

Gilead Sciences

This stock is trading a very reasonable 9.05 times estimated 2022 earnings and has big-time upside potential. Gilead Sciences Inc. (NASDAQ: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in the areas of unmet medical need in the United States, Europe and elsewhere.

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.